s
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain
15-05-2024, 12:01
TORONTO, May 15, 2024 /PRNewswire/ — AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management. AMT-143 is a local slow-release non-opioid local anesthetic that would leverage the AmacaGel platform […] L'articolo AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain proviene da La Ragione.
CONTINUA A LEGGERE
11
0
0
Guarda anche
La Ragione
09:09
Morto Sammy Basso, il 28enne malato di Progeria
La Ragione
08:59
Mo: Idf, ‘colpiti siti stoccaggio armi Hezbollah’
La Ragione
08:57
La stupida violenza
La Ragione
08:48